Atlas Trials

A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis

Clinical trial NCT00535782 · COMPLETED

Trial details

NCT number
NCT00535782
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Rheumatoid Arthritis
Start date
2007-10-31
Primary completion
2008-09-30
Enrollment
132

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.